These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

968 related items for PubMed ID: 31169926

  • 1. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A.
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [Abstract] [Full Text] [Related]

  • 2. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F.
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [Abstract] [Full Text] [Related]

  • 3. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
    Dupré A, Collins M, Nocturne G, Carbonnel F, Mariette X, Seror R.
    Rheumatology (Oxford); 2020 Nov 01; 59(11):3275-3283. PubMed ID: 32259251
    [Abstract] [Full Text] [Related]

  • 4. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
    Lamichhane N, Melas N, Bergqvist V, SWIBREG, Ekholm NP, Olén O, Ludvigsson JF, Hjortswang H, Marsal J, Eriksson C, Halfvarson J.
    Dig Dis Sci; 2024 Jun 01; 69(6):2175-2183. PubMed ID: 38637457
    [Abstract] [Full Text] [Related]

  • 5. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
    Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, Kim ES, Jung Y, Eun CS, Kim TO, Kang SB, Kim YS, Seo GS, Lee CK, Im JP, Park SJ, Park DI, Ye BD.
    Inflamm Bowel Dis; 2021 Nov 15; 27(12):1931-1941. PubMed ID: 33501935
    [Abstract] [Full Text] [Related]

  • 6. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
    Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A.
    Inflamm Bowel Dis; 2018 Aug 16; 24(9):1876-1882. PubMed ID: 29668916
    [Abstract] [Full Text] [Related]

  • 7. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
    Reinglas J, Gonczi L, Verdon C, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.
    Dig Dis Sci; 2020 Jul 16; 65(7):2046-2053. PubMed ID: 31813132
    [Abstract] [Full Text] [Related]

  • 8. An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study.
    D'Amico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, Moreira P, Silva I, Bosca-Watts M, Innocenti T, Dragoni G, Bezzio C, Zilli A, Furfaro F, Saibeni S, Chaparro M, García MJ, Michalopoulos G, Viazis N, Mantzaris GJ, Ellul P, Gisbert JP, Magro F, Peyrin-Biroulet L, Armuzzi A, Ungaro F, Danese S, Fiorino G, Allocca M.
    Eur J Clin Invest; 2024 Nov 16; 54(11):e14283. PubMed ID: 38979834
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
    Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.
    Inflamm Bowel Dis; 2018 Oct 12; 24(11):2442-2451. PubMed ID: 29788318
    [Abstract] [Full Text] [Related]

  • 10. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
    Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN.
    Aliment Pharmacol Ther; 2019 Apr 12; 49(7):873-879. PubMed ID: 30773667
    [Abstract] [Full Text] [Related]

  • 11. Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
    Chan W, Lynch N, Bampton P, Chang J, Chung A, Florin T, Hetzel DJ, Jakobovits S, Moore G, Pavli P, Radford-Smith G, Thin L, Baraty B, Haifer C, Yau Y, Leong RWL.
    Eur J Gastroenterol Hepatol; 2018 Jul 12; 30(7):735-740. PubMed ID: 29727386
    [Abstract] [Full Text] [Related]

  • 12. Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease.
    Jossen J, Kiernan BD, Pittman N, Dubinsky MC.
    J Pediatr Gastroenterol Nutr; 2020 Mar 12; 70(3):304-309. PubMed ID: 31738290
    [Abstract] [Full Text] [Related]

  • 13. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW.
    J Crohns Colitis; 2019 Sep 19; 13(9):1111-1120. PubMed ID: 30768123
    [Abstract] [Full Text] [Related]

  • 14. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
    Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS.
    Inflamm Bowel Dis; 2018 Oct 12; 24(11):2461-2467. PubMed ID: 29788240
    [Abstract] [Full Text] [Related]

  • 15. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
    Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, Rimmer JE, De La Revilla Negro J, Pavey H, Pele L, Brooks J, Moran GW, Irving PM, Limdi JK, Lamb CA, UK IBD BioResource Investigators , Parkes M, Raine T.
    J Crohns Colitis; 2024 Jun 03; 18(6):790-800. PubMed ID: 38041850
    [Abstract] [Full Text] [Related]

  • 16. Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease-EXVEDOCOL.
    Parra V, Cifuentes S, Avendaño S, Ponce de León E, Florez C, Reyes G, Puentes F, Ballesteros M, Nuñez E, Gómez F, Márquez JR.
    Gastroenterol Hepatol; 2024 Oct 03; 47(8):858-866. PubMed ID: 38311006
    [Abstract] [Full Text] [Related]

  • 17. Introducing vedolizumab to clinical practice: who, when, and how?
    Bryant RV, Sandborn WJ, Travis SP.
    J Crohns Colitis; 2015 Apr 03; 9(4):356-66. PubMed ID: 25687206
    [Abstract] [Full Text] [Related]

  • 18. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC, Bressler B.
    Immunotherapy; 2014 Apr 03; 6(9):963-71. PubMed ID: 25341118
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
    Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O, Lichtenstein L, Bar-Gil Shitrit A, Israeli E, Schwartz D, Zittan E, Eliakim R, Chowers Y, Ben-Horin S, Dotan I.
    Inflamm Bowel Dis; 2017 Mar 03; 23(3):404-408. PubMed ID: 28178003
    [Abstract] [Full Text] [Related]

  • 20. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
    Rath T, Billmeier U, Ferrazzi F, Vieth M, Ekici A, Neurath MF, Atreya R.
    Front Immunol; 2018 Mar 03; 9():1700. PubMed ID: 30131801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.